Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Omega Therapeutics, Inc. (OMGAQ : OTC)

• Company Description    Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass. Number of Employees: 94

• Price / Volume Information    Yesterday's Closing Price: $0.09 Daily Weekly Monthly 20 Day Moving Average: 745,570 shares Shares Outstanding: 55.37 (millions) Market Capitalization: $4.71 (millions) Beta: 0.63 52 Week High: $0.19 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 203.93% 192.55% 12 Week 54.73% 30.15% Year To Date -88.59% -89.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 140 First Street Suite 501 - CAMBRIDGE,MA 02141 USA ph: 617-949-4360 fax: - ir@omegatherapeutics.com http://www.omegatherapeutics.com

• General Corporate Information    Officers Mahesh Karande - President; Chief Executive Officer and Director Christian S. Schade - Chairman of the Board of Directors Joshua Reed - Chief Financial Officer Rainer Boehm - Director Luke M. Beshar - Director Peer Information Omega Therapeutics, Inc. (CORR.) Omega Therapeutics, Inc. (RSPI) Omega Therapeutics, Inc. (CGXP) Omega Therapeutics, Inc. (BGEN) Omega Therapeutics, Inc. (GTBP) Omega Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68217N105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 55.37 Most Recent Split Date: (:1) Beta: 0.63 Market Capitalization: $4.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: 0.58 EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 214.32% vs. Previous Quarter: 22.40% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©